Nutriband Inc. (NASDAQ:NTRB) Short Interest Down 51.1% in October

Nutriband Inc. (NASDAQ:NTRB) was the target of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 41,800 shares, a decrease of 51.1% from the October 15th total of 85,400 shares. Currently, 0.9% of the shares of the company are sold short. Based on an average daily volume of 32,900 shares, the days-to-cover ratio is presently 1.3 days.

Nutriband Stock Performance

Shares of NTRB traded down $0.24 during trading hours on Wednesday, hitting $4.81. The company’s stock had a trading volume of 19,319 shares, compared to its average volume of 35,255. The business has a 50 day simple moving average of $5.84 and a two-hundred day simple moving average of $5.57. Nutriband has a 52-week low of $2.04 and a 52-week high of $9.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.57 and a quick ratio of 6.36. The company has a market cap of $53.44 million, a price-to-earnings ratio of -5.72 and a beta of 1.12.

Nutriband (NASDAQ:NTRB) last announced its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.12) earnings per share for the quarter. Nutriband had a negative net margin of 401.39% and a negative return on equity of 66.60%. The company had revenue of $0.44 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Nutriband stock. Virtu Financial LLC acquired a new position in shares of Nutriband Inc. (NASDAQ:NTRB) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 12,862 shares of the company’s stock, valued at approximately $58,000. Virtu Financial LLC owned approximately 0.12% of Nutriband at the end of the most recent quarter. Institutional investors and hedge funds own 19.70% of the company’s stock.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.